International Pharmaceutical Contract

Table of Contents

Introduction3

Problem Statement4

Research Study4

Determinants of the Problems4

Contract Options5

Purpose of the Study9

Rationale of the Study10

Literature Review10

Background10

Methodology13

Study Design13

Data Collection and Sampling14

Interviews15

Results16

Implications for practice17

Limitations17

Paternalism17

International Pharmaceutical Contract18

Conclusion24

International Pharmaceutical Contract

Introduction

The pharmaceutical industry came from a diverse range of activities related to the production of substances used in medicine. Pharmacists and chemists produce different preparations with these substances, such as extracts, tinctures, mixtures, lotions, ointments or pills. The pharmaceutical industry is the economic sector which includes research, manufacturing and marketing of drugs for medical or veterinary practitioners (Sismondo, 2008). The international pharmaceutical contract is a branch of the development, production and marketing of licensed drugs and medicines. This branch features a variety of forms of legislation and government regulation regarding patenting of drugs and testing their effectiveness and safety after production.

For a better understanding of the functioning of the pharmaceutical industry, it is imperative that an understanding of the key concepts is developed. This includes gaining an understanding of drugs and their development, and aiding the discovery of new drugs. In the past, drugs were traditionally produced through the process of separation. This process involved the separation and isolation of the active ingredients in traditional medicine. Some medicines were also invented through accidental discoveries. Modern biotechnology puts great emphasis on the study of the metabolic processes which occur during a particular disease state or pathogen. They use molecular biology and biochemistry for this purpose. Much of the early stages of drug discovery were carried out by universities and research organizations.

International pharmaceutical contracts govern the pharmaceutical industry and define a set of industry variables such as research and development, patent life, medical science, and regulatory constraints which preclude parallels from other manufacturing models and industries. Although there are many articles and consultant work that address outsourcing of various business processes and/or services, understanding the key challenges of negotiation and drafting an effective and watertight pharmaceutical contract on an international level is a complex topic in such a highly regulated industry.

Problem Statement

It may be said that allocation is an international pharmaceutical contract health problem, looking at how producing a drug with side effects exposes patients to a myriad of health problems. Pharmaceutical companies involved in the production of medicines have been the subject of scrutiny because of potential unexpected side effects and related health problems in patients.

Research Study

Determinants of the Problems

After hospitals, prescribed and non-prescribed drugs constitute the second biggest share of expenditures in the healthcare sector. Debates on international pharmaceutical contracts across the globe have primarily been focused on ensuring that cost-containment is balanced and the demand for pharmaceuticals is addressed. Apart from this, although a global environment has been established in a way that is highly conducive in terms of promoting research and development among manufacturers of pharmaceutical products, additional tensions have also surfaced, which have forced policymakers to consider revising international contracts and allowing concessions in order to allow them to manage pharmaceutical expenses.

Contract Options

A wide range of contract options are available for the successful completion of this research study. These contracts are discussed below and ...